Freespira

Freespira is a commercial-stage digital therapeutics company offering a non-medication, device-based treatment for panic attacks and PTSD. Its FDA-cleared system addresses physiological dysregulation linked to these conditions by training users to normalize their breathing and CO2 sensitivity. The company has demonstrated strong clinical results, including high rates of patients remaining panic attack-free one year post-treatment, and is now expanding its reach to adolescents. Its business model focuses on B2B partnerships with payers and providers to drive adoption.

A digital therapeutic platform combining a disposable breathing sensor and tablet software that provides real-time biofeedback to normalize breathing rate and end-tidal CO2 levels, aimed at retraining the autonomic nervous system over a 28-day treatment period. It is paired with remote clinical support.

Freespira competes in the broad digital mental health market, which includes general meditation apps (Calm, Headspace), telehealth therapy platforms (BetterHelp, Talkspace), and other FDA-cleared digital therapeutics for mental health (e.g., Pear Therapeutics' reSET for SUD). Its primary differentiation is its FDA clearance for specific disorders, its focus on physiological dysregulation, and its structured, time-limited protocol with proven long-term outcomes.